- Home
- RLMD
as 07-26-2024 4:00pm EST
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 90.5M | IPO Year: | N/A |
| Target Price: | $2.00 | AVG Volume (30 days): | 120.3K |
| Analyst Decision: | Strong Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.42 - $7.22 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Relmada Therapeutics Inc. (RLMD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Jan 29 '24 | Buy | $3.71 | 31,541 | $117,036.03 | 175,565 | SEC Form 4 |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Jan 29 '24 | Buy | $3.90 | 40,999 | $159,949.40 | 216,564 | SEC Form 4 |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Jan 29 '24 | Buy | $4.00 | 27,460 | $109,752.13 | 244,024 | SEC Form 4 |
| Ence Chuck | RLMD | CA and CO | Jan 29 '24 | Buy | $3.65 | 10,800 | $39,438.36 | 10,800 | SEC Form 4 |
| Ence Chuck | RLMD | CA and CO | Jan 29 '24 | Buy | $3.87 | 14,500 | $56,052.65 | 25,300 | SEC Form 4 |
| Ence Chuck | RLMD | CA and CO | Jan 29 '24 | Buy | $4.05 | 13,670 | $55,429.12 | 38,970 | SEC Form 4 |
| Shenouda Maged | RLMD | Chief Financial Officer | Jan 29 '24 | Buy | $3.65 | 10,800 | $39,450.24 | 13,028 | SEC Form 4 |
| Shenouda Maged | RLMD | Chief Financial Officer | Jan 29 '24 | Buy | $3.89 | 15,000 | $58,323.00 | 28,028 | SEC Form 4 |
| Shenouda Maged | RLMD | Chief Financial Officer | Jan 29 '24 | Buy | $4.06 | 6,875 | $27,943.44 | 34,903 | SEC Form 4 |
Latest Relmada Therapeutics Inc. News
RLMD Breaking Stock News: Dive into RLMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership
PR Newswire
a month ago
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
PR Newswire
2 months ago
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR Newswire
2 months ago
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Insider Monkey
3 months ago
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Thomson Reuters StreetEvents
3 months ago
Q1 2024 Relmada Therapeutics Inc Earnings Call
GuruFocus.com
3 months ago
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
PR Newswire
3 months ago
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Compare RLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLMD Relmada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.